Harmony Biosciences Holdings, Inc. (HRMY) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$42.57

From 52W high−1.96%

Volume3.63M

Market cap$2.45B

P/E (TTM)13.4x

P/S (TTM)2.5x

Div yield—

Key dataSep 18, 2026

Open

$42.57

From 52W high

−1.96%

Volume

3.63M

Market cap

$2.45B

ValuationView details →

P/E (Fwd)

10.5x

EV/EBITDA

7.0x

P/E (TTM)

13.4x

RSI (14)

61.0

MomentumView details →

1D Return

−1.68%

YTD Return

+12.71%

SummaryUpdated Jun 1, 2026

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is a commercial-stage pharmaceutical company founded in 2017 and based in Plymouth Meeting, Pennsylvania. The company went public in August 2020 and has established itself as a profitable biotechnology firm focused exclusively on developing and commercializing therapies for patients with rare neurological disorders. Since its founding, Harmony has built a robust pipeline of eight assets across three distinct therapeutic franchises, with its flagship product WAKIX generating over $2 billion in cumulative sales since launch.

Ask drillr about Harmony Biosciences Holdings, Inc. →

ValuationView details →

P/E (Fwd)

10.5x

P/E (TTM)

13.4x

EV/EBITDA

7.0x

EV/Sales

2.0x

P/S (TTM)

2.5x

P/B (TTM)

2.4x

ProfitabilityView details →

Gross Margin

75.42%

Net Margin

18.88%

EBITDA Margin

28.79%

ROE (TTM)

18.14%

ROA (TTM)

13.20%

Asset Turnover

0.73x

GrowthView details →

Revenue YoY

+24.25%

EPS YoY

−1.26%

FCF YoY

+37.17%

Revenue CAGR 3Y

+25.64%

EPS CAGR 3Y

−3.49%

EBITDA YoY

+4.28%

MomentumView details →

1D Return

−1.68%

YTD Return

+12.71%

1Y Return

+29.61%

RSI (14)

61.0

vs 50D SMA

+9.65%

vs 200D SMA

+22.05%

Capital & dividendView details →

Debt/Equity

0.15x

Current Ratio

3.48x

Quick Ratio

3.45x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

$1.28

EPS Surprise

33.89%

Beats (12Q)

8/12

Next Q EPS Est

$1.11

Avg Surprise (4Q)

−13.48%

Rev Surprise

4.19%

Financials snapshotView financials →

Revenue (TTM)

959.90M

Net Income (TTM)

181.27M

Op. CF (TTM)

355.08M

Next earningsNov 3, 2026 →

Latest newsMore news →

Aurora Investment Counsel acquired a new position in Harmony Biosciences Holdings, Inc., purchasing 65,148 shares valued at approximately $2.37 million, as disclosed in a recent SEC filing.31d ago

Harmony Biosciences highlighted record quarterly performance for its narcolepsy treatment WAKIX and outlined development plans across its orexin, epilepsy and pitolisant lifecycle-management programs during Piper Sandler's virtual CNS Symposium.37d ago

Similar companies

Vera Therapeutics, Inc.VERA Mineralys Therapeutics, Inc.MLYS Viridian Therapeutics, Inc.VRDN Structure Therapeutics Inc.GPCR 东亚药业605177.SH Pharvaris N.V.PHVS Find similar companies →

Latest newsMore news →

Aurora Investment Counsel acquired a new position in Harmony Biosciences Holdings, Inc., purchasing 65,148 shares valued at approximately $2.37 million, as disclosed in a recent SEC filing.31d ago Harmony Biosciences highlighted record quarterly performance for its narcolepsy treatment WAKIX and outlined development plans across its orexin, epilepsy and pitolisant lifecycle-management programs during Piper Sandler's virtual CNS Symposium.37d ago Harmony Biosciences announced initial Phase 1 clinical data for its orexin-2 agonist BP-205, showing favorable pharmacokinetic and safety profiles, and plans to initiate Phase 1b and Phase 2 trials in 2026 and 2027.47d ago